Coeptis Therapeutics 

$0.01
15
-$0-8.18% Friday 17:49

Statistics

Day High
0.01
Day Low
0.01
52W High
0.01
52W Low
0.01
Volume
57,030
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1
-0.71
-0.41
-0.12
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2005
2018
2019
2020
2021
2022
0Revenue
-74.88MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow COEPW. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that competes in the development of innovative therapies, similar to Coeptis Therapeutics' focus on novel treatments.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech firm that develops therapeutic solutions in various disease areas, competing with Coeptis Therapeutics in the biopharmaceutical space.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines, making it a competitor in the pharmaceutical and biotech industry.
Merck
MRK
Mkt Cap298.84B
Merck operates in the pharmaceutical sector, focusing on innovative drug development and directly competing with companies like Coeptis Therapeutics.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is a global biopharmaceutical company with a wide range of products and research areas, overlapping with Coeptis Therapeutics' interests.
Novartis
NVS
Mkt Cap297.32B
Novartis is a healthcare company that engages in the research, development, and marketing of healthcare products, competing in the same space as Coeptis Therapeutics.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie is a research-based biopharmaceutical company, its diverse range of pharmaceutical products places it in competition with Coeptis Therapeutics.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, making it a competitor in the healthcare sector.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson is a comprehensive healthcare firm that competes across various segments, including pharmaceuticals, which overlaps with Coeptis Therapeutics' operations.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals is a leading biotechnology company that develops and commercializes medicines for serious medical conditions, competing in the biopharmaceutical field.

About

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Show more...
CEO
Mr. David Mehalick
Employees
4
Country
United States
ISIN
US19207A1161

Listings

0 Comments

Share your thoughts

FAQ

What is Coeptis Therapeutics stock price today?
The current price of COEPW is $0.01 USD — it has decreased by -8.18% in the past 24 hours. Watch Coeptis Therapeutics stock price performance more closely on the chart.
What is Coeptis Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Coeptis Therapeutics stocks are traded under the ticker COEPW.
Is Coeptis Therapeutics stock price growing?
COEPW stock has risen by +2.03% compared to the previous week, the month change is a -16.53% fall, over the last year Coeptis Therapeutics has showed a +26.25% increase.
When is the next Coeptis Therapeutics earnings date?
Coeptis Therapeutics is going to release the next earnings report on June 03, 2026.
What is Coeptis Therapeutics revenue for the last year?
Coeptis Therapeutics revenue for the last year amounts to 0 USD.
What is Coeptis Therapeutics net income for the last year?
COEPW net income for the last year is -74.88M USD.
How many employees does Coeptis Therapeutics have?
As of April 12, 2026, the company has 4 employees.
In which sector is Coeptis Therapeutics located?
Coeptis Therapeutics operates in the Health & Wellness sector.
When did Coeptis Therapeutics complete a stock split?
Coeptis Therapeutics has not had any recent stock splits.
Where is Coeptis Therapeutics headquartered?
Coeptis Therapeutics is headquartered in Wexford, United States.